Last updated: February 21, 2026
What is NDC 62011-0199?
NDC 62011-0199 is marketed as Zynlonta (loncastuximab tesirine-lpyl). It is a CD19-directed antibody-drug conjugate indicated for relapsed or refractory large B-cell lymphoma (LBCL) after at least two prior lines of systemic therapy. FDA approval was granted in April 2021.
Market Landscape
Target Population
The primary market includes adult patients with relapsed/refractory LBCL. According to the American Cancer Society, approximately 75,000 new cases of non-Hodgkin lymphoma (NHL) are diagnosed annually in the U.S., with about 30-40% classified as LBCL.
- Estimated U.S. patients eligible for Zynlonta: ~10,000 annually.
- Competitive landscape includes CAR-T therapies (e.g., Axicabtagene ciloleucel), beginning to saturate the second-line setting.
Current Market Adoption
Zynlonta is in the early commercialization phase in the U.S. It competes with established therapies like:
- CD19 CAR-T treatments (Yescarta, Breyanzi)
- Other antibody-drug conjugates (e.g., Polivy)
Despite its approval, clinicians have demonstrated cautious adoption, prioritizing CAR-T for eligible patients and considering Zynlonta for relapsed cases where CAR-T is unfeasible.
Sales Drivers
- Unmet need in relapse/refractory LBCL
- Existing treatment pipelines and approvals
- Competitive positioning as a non-cellular alternative with a different safety profile
Pricing Analysis
Current Price Points
As of mid-2023, list price for Zynlonta is approximately $18,350 per infusion. The standard treatment course involves three infusions, totaling approximately $55,050.
Price Comparison
| Drug |
Indication |
List Price per Course |
Cost Components |
| Zynlonta (NDC 62011-0199) |
R/R LBCL |
$55,050 |
3 infusions |
| Yescarta (axicabtagene ciloleucel) |
R/R LBCL |
$373,000 |
Single infusion |
| Polivy (polatuzumab vedotin) |
R/R LBCL |
$13,500 per dose |
6 doses |
Zynlonta is priced substantially lower than CAR-T therapies but higher than other antibody-drug conjugates.
Cost-Effectiveness Considerations
- Clinical outcomes such as overall response rate (ORR) and progression-free survival (PFS) influence price endurance.
- Zynlonta has demonstrated ORR of approximately 60% in clinical studies, with durable responses in a subset of patients.
- Its positioning as an outpatient, non-cell therapy offers potential cost-savings over CAR-T, which involves hospitalization and managing cytokine release syndrome.
Market Penetration and Projections
Near-term Projections (2023-2025)
- Estimated first-year sales: $50 million.
- Growth rate: 15-20% annually, driven by increased physician familiarity and expanding indications.
- Potential maximum market share: 10-15% among relapsed/refractory LBCL patients, given competition.
Long-term Outlook (2026 and beyond)
- With approved expansion into earlier-line treatment and other B-cell lymphomas, sales could approach $200 million annually.
- Novel combination therapies and real-world evidence are expected to shape future adoption.
Factors Impacting Prices
- Evolving reimbursement policies.
- Biosimilar or generic antibody-drug conjugates entering the market.
- Adoption rates influenced by clinical guidelines and comparator performance.
Key Market Risks
- Competitive pressure from CAR-T and other ADCs.
- Slow adoption in relapsed/refractory setting.
- Reimbursement hurdles and pricing negotiations.
Summary
| Aspect |
Details |
| Average annual sales (2023-2024) |
~$50-70 million |
| Price per course |
~$55,000 |
| Market share potential |
Up to 15% of R/R LBCL |
| Long-term sales outlook |
$150-$200 million annually |
Key Takeaways
- NDC 62011-0199, Zynlonta, entered an early-growth phase with a price around $55,000 per course.
- The drug targets a niche with high unmet medical needs but faces competition from CAR-T therapies.
- Market adoption will depend heavily on clinical outcomes, reimbursement policies, and comparative pricing.
- Revenue growth is projected to accelerate as clinical experience expands and indications broaden.
- Price sensitivity among payers and competing therapies could alter the growth trajectory.
FAQs
Q1: How does Zynlonta's price compare to CAR-T therapies?
CAR-T therapies like Yescarta cost over $370,000 per treatment, significantly higher than Zynlonta’s $55,000 course price.
Q2: What factors influence future price adjustments?
Reimbursement negotiations, clinical outcomes, market competition, and manufacturing costs.
Q3: Is Zynlonta likely to see price reductions?
Potentially, if biosimilars or alternative ADCs enter the market or if payers negotiate discounts.
Q4: What is the main driver for sales growth?
Clinical adoption in relapsed/refractory LBCL patients and approval for broader indications.
Q5: What is the risk of market saturation?
High, due to established CAR-T therapies and emerging treatments; growth depends on differentiation and clinical success.
References
- American Cancer Society. (2022). Non-Hodgkin Lymphoma. Retrieved from https://www.cancer.org/cancer/non-hodgkin-lymphoma.html
- FDA. (2021). Approval Notice for Zynlonta. https://www.fda.gov
- MarketWatch. (2023). Oncology drug prices and sales estimates. Retrieved from https://www.marketwatch.com
- IQVIA. (2023). U.S. Oncology Market Insights.
